Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 40

Cited In for PubMed (Select 8285810)

1.

Conflicts of interest among authors of clinical practice guidelines for glycemic control in type 2 diabetes mellitus.

Norris SL, Holmer HK, Ogden LA, Burda BU, Fu R.

PLoS One. 2013 Oct 14;8(10):e75284. doi: 10.1371/journal.pone.0075284. eCollection 2013.

2.

SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.

Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleza-Jeric K, Laupacis A, Moher D.

BMJ. 2013 Jan 8;346:e7586. doi: 10.1136/bmj.e7586.

3.

Conflict of interest disclosures for clinical practice guidelines in the national guideline clearinghouse.

Norris SL, Holmer HK, Ogden LA, Selph SS, Fu R.

PLoS One. 2012;7(11):e47343. doi: 10.1371/journal.pone.0047343. Epub 2012 Nov 7. Erratum in: PLoS One. 2013;8(8). doi:10.1371/annotation/1b125769-1f74-4225-94b8-bd2c80adae1f.

4.

Recognizing, investigating and dealing with incomplete and biased reporting of clinical research: from Francis Bacon to the WHO.

Dickersin K, Chalmers I.

J R Soc Med. 2011 Dec;104(12):532-8. doi: 10.1258/jrsm.2011.11k042. No abstract available. Erratum in: J R Soc Med. 2012 Mar;105(3):96.

5.

Industry and evidence-based medicine: Believable or conflicted? A systematic review of the surgical literature.

Bailey CS, Fehlings MG, Rampersaud YR, Hall H, Wai EK, Fisher CG.

Can J Surg. 2011 Oct;54(5):321-6. doi: 10.1503/cjs.008610. Review.

6.

Modified versus standard intention-to-treat reporting: are there differences in methodological quality, sponsorship, and findings in randomized trials? A cross-sectional study.

Montedori A, Bonacini MI, Casazza G, Luchetta ML, Duca P, Cozzolino F, Abraha I.

Trials. 2011 Feb 28;12:58. doi: 10.1186/1745-6215-12-58.

7.

The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials.

Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K.

Dtsch Arztebl Int. 2010 Apr;107(16):279-85. doi: 10.3238/arztebl.2010.0279. Epub 2010 Apr 23. Review.

8.

Relationships between authorship contributions and authors' industry financial ties among oncology clinical trials.

Rose SL, Krzyzanowska MK, Joffe S.

J Clin Oncol. 2010 Mar 10;28(8):1316-21. doi: 10.1200/JCO.2008.21.6606. Epub 2010 Jan 11.

9.

Association of trial registration with the results and conclusions of published trials of new oncology drugs.

Rasmussen N, Lee K, Bero L.

Trials. 2009 Dec 16;10:116. doi: 10.1186/1745-6215-10-116.

10.

Barriers to physician adherence to nonsteroidal anti-inflammatory drug guidelines: a qualitative study.

Cavazos JM, Naik AD, Woofter A, Abraham NS.

Aliment Pharmacol Ther. 2008 Sep 15;28(6):789-98.

11.

Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation.

Rising K, Bacchetti P, Bero L.

PLoS Med. 2008 Nov 25;5(11):e217; discussion e217. doi: 10.1371/journal.pmed.0050217. Erratum in: PLoS Med. 2009 Jan;6(1). doi: 10.1371/journal.Pmed.1000017.

12.

Evolution of the randomized controlled trial in oncology over three decades.

Booth CM, Cescon DW, Wang L, Tannock IF, Krzyzanowska MK.

J Clin Oncol. 2008 Nov 20;26(33):5458-64. doi: 10.1200/JCO.2008.16.5456. Epub 2008 Oct 27.

13.

Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions.

Jørgensen AW, Maric KL, Tendal B, Faurschou A, Gøtzsche PC.

BMC Med Res Methodol. 2008 Sep 9;8:60. doi: 10.1186/1471-2288-8-60.

14.

Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?

Golder S, Loke YK.

Br J Clin Pharmacol. 2008 Dec;66(6):767-73. doi: 10.1111/j.1365-2125.2008.03272.x. Epub 2008 Jul 31. Review.

15.

Abstracts in high profile journals often fail to report harm.

Bernal-Delgado E, Fisher ES.

BMC Med Res Methodol. 2008 Mar 27;8:14. doi: 10.1186/1471-2288-8-14. Review.

17.

Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review.

Jørgensen AW, Hilden J, Gøtzsche PC.

BMJ. 2006 Oct 14;333(7572):782. Epub 2006 Oct 6. Review.

19.

Medical journals are an extension of the marketing arm of pharmaceutical companies.

Smith R.

PLoS Med. 2005 May;2(5):e138. Epub 2005 May 17. No abstract available.

20.

The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review.

Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D.

BMJ. 2004 Oct 23;329(7472):948. Epub 2004 Oct 8. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk